Biotech Startups, Policy, and the Law: A Conversation with Dr. Hans Sauer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ce/aa/ae/ceaaaeb1-f949-3c71-b6e8-8fc3e5e06228/mza_12151924103712158896.jpg/600x600bb.jpg

Intersection of Biotechnology, Ethics, and the Law

Delia Narrai

4 episodes

3 hours ago

Hosted by high school student Delia Narrai, Intersection: Biotechnology, Ethics & Law dives into the breakthroughs shaping our future—and the questions we’re still figuring out. Through conversations with scientists, lawyers, and thought leaders, Delia explores how innovation in biotechnology intersects with ethics, policy, and society. Made for curious students and future changemakers, this podcast is about asking the right questions, not just finding easy answers

Science

RSS

All content for Intersection of Biotechnology, Ethics, and the Law is the property of Delia Narrai and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/44062479/44062479-1752437564846-91807f4d16204.jpg

Biotech Startups, Policy, and the Law: A Conversation with Dr. Hans Sauer

Intersection of Biotechnology, Ethics, and the Law

54 minutes 38 seconds

1 month ago

Biotech Startups, Policy, and the Law: A Conversation with Dr. Hans Sauer

What’s really at stake when a biotech startup tries to bring something new into the world?

In this episode, I speak with Dr. Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property at the Biotechnology Innovation Organization (BIO) and adjunct professor of law at Georgetown Law School. With a legal and scientific career spanning biotech patents, policy, and entrepreneurship, Dr. Sauer shares a big-picture view of what’s working—and what’s still unfolding—in today’s biotech landscape.

We talk about the key legal and ethical questions facing biotech startups, how intellectual property influences innovation, and how the biotech sector is pushing law and policy to evolve. It’s a wide-ranging and grounded conversation about the real frameworks that shape biotech outcomes.